Literature DB >> 32497490

Chasing the cabotegravir tail: implications for prevention.

Kimberly K Scarsi1.   

Abstract

Year:  2020        PMID： 32497490     DOI： 10.1016/S2352-3018(20)30165-X

Source DB:  PubMed          Journal:  Lancet HIV        ISSN： 2352-3018            Impact factor:   12.767


× No keyword cloud information.
  2 in total

1.  Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.

Authors:  Suyash Deodhar; Brady Sillman; Aditya N Bade; Sean N Avedissian; Anthony T Podany; JoEllyn M McMillan; Nagsen Gautam; Brandon Hanson; Bhagya L Dyavar Shetty; Adam Szlachetka; Morgan Johnston; Michellie Thurman; Daniel J Munt; Alekha K Dash; Milica Markovic; Arik Dahan; Yazen Alnouti; Alborz Yazdi; Bhavesh D Kevadiya; Siddappa N Byrareddy; Samuel M Cohen; Benson Edagwa; Howard E Gendelman
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

2.  Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments.

Authors:  Simone Perazzolo; Subhra Mandal; Pavan K Prathipati; Christopher J Destache
Journal:  Front Pharmacol       Date:  2020-12-18       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.